Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis, And Covid-19.
Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.